Zobrazeno 1 - 9
of 9
pro vyhledávání: '"S. I. Varentsov"'
Autor:
A. A. Kulievа, E. I. Emelina, G. E. Gendlin, I. G. Nikitin, S. K. Zyryanov, S. I. Varentsov, I. I. Zakharova
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 55-65 (2020)
Cardiovascular toxicity of cancer therapies remains an urgent problem today. The creation of highly effect antitumor drugs also means the appearance of new adverse effects. Immune checkpoint inhibitors (ICI) is a new class of antitumor drugs that is
Externí odkaz:
https://doaj.org/article/23ade83b8eca4366b741089ccfd48653
Publikováno v:
КардиоСоматика, Vol 5, Iss 3-4, Pp 48-53 (2014)
The paper presents the study of a new anti-anginal drug - sodium channel inhibitor ranolazine. Considered antianginal, anti-ischemic effect of the drug. Described reduction in angina attacks, increased exercise tolerance and quality of life of patien
Externí odkaz:
https://doaj.org/article/129cdecd50c14c428658f77c9699ed53
Publikováno v:
КардиоСоматика, Vol 5, Iss 2, Pp 46-50 (2014)
The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in
Externí odkaz:
https://doaj.org/article/6ff6886b086e402aa285c077df761800
Autor:
G. E. Gendlin, I. I. Zakharova, E. F. Dadashova, E. M. Alekseeva, S. I. Varentsov, Igor G. Nikitin, A. V. Melekhov
Publikováno v:
Russian Heart Journal. 16:73-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3c2e0a518f38c4dd147534cd8ad631d
https://doi.org/10.18087/rhj.2017.1.2296
https://doi.org/10.18087/rhj.2017.1.2296
Publikováno v:
КардиоСоматика, Vol 5, Iss 2, Pp 46-50 (2014)
The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab2d1c4b61bfb0438477c34f1f07767
https://doi.org/10.26442/cs45099
https://doi.org/10.26442/cs45099
Publikováno v:
Системные гипертензии, Vol 11, Iss 1, Pp 64-72 (2014)
The following review assesses socially significant disease - hypertension (AH) - and the problem of finding an effective antihypertensive therapy. Twynsta® drug (manufacturer Boehringer Ingelheim Pharma) - modern combined antihypertensive drug, whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a9b1335f98439bf9c12735b922ec5a
https://doi.org/10.26442/sg29014
https://doi.org/10.26442/sg29014
Publikováno v:
Системные гипертензии, Vol 10, Iss 4, Pp 76-79 (2013)
The data from clinical trials that have examined the efficacy and safety of modern third generation calcium antagonist-lercanidipine is presented herein. Results of the following studies demonstrate that treatment with lercanidipine leads to a marked
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253c34ce904929a424c8f21c03f9e4e9
https://doi.org/10.26442/sg28996
https://doi.org/10.26442/sg28996
Autor:
S I Varentsov, T V Bulargina, N G Gumanova, Y A Shakhov, C I Gerasimova, N. M. Akhmedzhanov, Kots AYa
Publikováno v:
Scopus-Elsevier
Acute ischemic heart disease is associated with alterations in the cardiac adenylate cyclase system response, although the specificity and mechanism of these events are unknown. We studied the characteristics of inhibitory (G(i)) and stimulatory (Gs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fad804db5130a82c48d4d3fbb772785a
http://www.scopus.com/inward/record.url?eid=2-s2.0-0027166072&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0027166072&partnerID=MN8TOARS
Publikováno v:
Системные гипертензии, Vol 11, Iss 1, Pp 64-72 (2014)
The following review assesses socially significant disease - hypertension (AH) - and the problem of finding an effective antihypertensive therapy. Twynsta® drug (manufacturer Boehringer Ingelheim Pharma) - modern combined antihypertensive drug, whic
Externí odkaz:
https://doaj.org/article/ec0ca4500d154b2893c0e35f26bca55c